Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Mirazid vs Praziquantel for Schistosomiasis
NCT01529710Phase 3Completed
- Sponsor
- Pharco Pharmaceuticals
- Start
- Dec 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of myrrh in schistosomiasis (2 arms), sponsored by Pharco Pharmaceuticals. Primary endpoints: Cure Rate at 12 weeks and Intensity of Infection Reduction at 12 weeks. Started Dec 2011; status: completed.
02
Drugs
myrrh
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT01529710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529710.